NL-OMON46500已完成不适用
Open-label, 2-period, fixed sequence study to assess the bioavailability of aluminium, formulated as aluminium chlorohydrate, after topical application of a representative antiperspirant formulation in healthy women using a [26Al] microtracer approach - Bioavailability of aluminium after topical application
Cosmetics Europe The Personal Care Association A.I.S.B.L.0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Healthy female subjects, 18 to 45 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a physical examination (with emphasis on the axilla) including vital signs, 12-lead ECG, haematology, blood chemistry, virology and urinalysis;
- •2. Body mass index (BMI) between 18 and 30 kg/m2, inclusive;
- •3. Able to communicate well with the investigator in the Dutch language;
- •4. Able to participate and willing to give written informed consent and to comply with the study restrictions;
- •5. Subjects should be used to frequent wet shaving with an appropriate female safety razor (electric shaving is not allowed, frequently is defined as at least three times a week);
- •6. Subjects should be used to frequent use of Al-containing product (frequently is defined as at least 5 times a week).
- •7. Sufficient venous access to allow blood sampling as per protocol.
排除标准
- •1. Any clinically significant abnormality as determined by medical history taking and physical examinations (e.g. scars, cuts, wounds, tattoos, and/or dermal abnormalities in the axilla) obtained during the screening visit that in the opinion of the investigator would interfere with the study objectives or compromise subject safety;
- •2. History of pathological scar formation (keloid, hypertrophic scars)
- •3. A positive pregnancy test and/or nursing at screening;
- •4. Use of aluminium-containing medications within 21 days prior to investigational product administrations, or less than 5 half-lives, whichever is longer, and during the course of the study;
- •5. Known allergy for aluminium;
- •6. Axillary hyperhydrosis (including subjects treated for this condition (e.g. with botox));
- •7. Clinically relevant abnormal laboratory results, ECG, vital signs, or physical findings at screening that in the opinion of the investigator would interfere with the study objectives or compromise subject safety;
- •8. Participation in an investigational drug study within 3 months prior to screening or more than 4 times in the past year; or participation in part A
- •9. Any psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol;
- •10. History of alcohol or illicit drug abuse (alcohol abuse defined as alcohol consumption > 28 units/week);
- •11. Donation of blood within 3 months prior to screening or donation of plasma within 14 days prior to screening;
- •12. Not having a general practitioner;
- •13. Not willing to accept information transfer which concerns participation in the study, or information regarding health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner;
- •14. Not willing to give permission to have the general practitioner to be notified upon participation in this study;
- •15. Not willing to use effective (double barrier) contraception until at least 3 months after last investigational product administration;
- •16. Subjects who are part of the site staff of CHDR or TNO employees;
- •17. Having a tattoo applied within 3 months prior to, or during the study.
研究者
相似试验
已完成
不适用
An open-label, two-period, fixed sequence study to evaluate the effects of multiple oral doses of AFQ056 on the pharmacokinetics of a monophasic oral contraceptive in healthy female volunteersFragile X Syndrome (FXS)interaction study1008362410029305mental retardationNL-OMON36456ovartis30
进行中（未招募）
不适用
Two-period, single-dose pharmacokinetic study in male adolescent patients with Fragile X Syndrome (FXS).Fragile X SyndromeMedDRA version: 14.0Level: PTClassification code 10017324Term: Fragile X syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-019353-18-Outside-EU/EEAovartis Pharma Services AG12
已完成
不适用
One-sequence, two-period, open-label study to evaluate the effects of FTY720 on the pharmacokinetics of an oral contraceptive (levonorgestrel/ethinyl estradiol) in healthy female volunteers.multiple sclerose10012303MSNL-OMON35177ovartis31
已完成
1 期
A DDI Study to Evaluate the Effects of Itraconazole and Fluoxetine on AK0529 in Healthy VolunteersRespiratory Syncytial Virus InfectionACTRN12619001413112Ark Biosciences Pty Ltd28
已完成
不适用
Two-groups, open label, fixed-sequence study to evaluate the effect of CYP3A4/P-gp inhibition (Itraconazole) or CYP1A2/3A4 inhibition (Fluvoxamine) on the single-dose PK of MEN1611 in healthy subjects.Cancer with PIK3CA mutationtumorsCancerNL-OMON51334Menarini Richerche S.p.A.44